{"id":"NCT02431247","sponsor":"Janssen Sciences Ireland UC","briefTitle":"A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects","officialTitle":"A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-06","primaryCompletion":"2017-03-02","completion":"2020-09-30","firstPosted":"2015-04-30","resultsPosted":"2018-09-14","lastUpdate":"2022-09-28"},"enrollment":725,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Immunodeficiency Virus Type 1, Human"],"interventions":[{"type":"DRUG","name":"Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC","otherNames":[]},{"type":"DRUG","name":"DRV/COBI FDC","otherNames":[]},{"type":"DRUG","name":"FTC/TDF FDC","otherNames":[]},{"type":"DRUG","name":"D/C/F/TAF FDC - Matching Placebo","otherNames":[]},{"type":"DRUG","name":"FTC/TDF FDC Matching Placebo","otherNames":[]},{"type":"DRUG","name":"DRV/COBI FDC Matching Placebo","otherNames":[]}],"arms":[{"label":"Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide","type":"EXPERIMENTAL"},{"label":"DRV/COBI fixed dose combination (FDC) and FTC/TDF FDC","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate non-inferiority in efficacy of a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus Darunavir/Cobicistat (DRV/COBI) FDC coadministered with Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC in human immunodeficiency virus-1 (HIV-1) infected, antiretroviral (ARV) treatment naive adult participants.","primaryOutcome":{"measure":"Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot Approach","timeFrame":"At Week 48","effectByArm":[{"arm":"D/C/F/TAF (Test) (Baseline to End of Extension [EOE])","deltaMin":91.4,"sd":88.1},{"arm":"DRV/COBI+ FTC/TDF (Control) (Baseline to Switch)","deltaMin":88.4,"sd":84.7}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":80,"countries":["United States","Belgium","Canada","France","Germany","Poland","Puerto Rico","Russia","Spain","United Kingdom"]},"refs":{"pmids":["34100149","31833849","31516033","31303147","29683855"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":47,"n":362},"commonTop":["Diarrhoea","Nasopharyngitis","Headache","Upper Respiratory Tract Infection","Syphilis"]}}